Position in CELC
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$58,782,100
-$1,261,380 QoQ
Shares Held
515,000
-14.5% QoQ
Ownership
1.06%
of shares outstanding
% of Portfolio
9.40%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Apis Capital Advisors, LLC holds $108,912,272 across 8 Biotechnology names. CELC ranks #1 (54.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CELC |
Celcuity Inc.
This page
|
515,000 | $58,782,100 | |
| 2 | ABVX |
Abivax S.A.
|
128,800 | $14,341,880 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
550,000 | $12,848,000 | |
| 4 | PVLA |
Palvella Therapeutics, Inc.
|
89,000 | $11,093,850 | |
| 5 | ANAB |
Anaptysbio, Inc
|
238,000 | $8,799,645 | |
| 6 | SLDB |
Solid Biosciences Inc.
|
160,000 | $1,152,000 | |
| 7 | DYAI |
Dyadic International Inc
|
1,270,972 | $1,042,197 | |
| 8 | CGEM |
Cullinan Therapeutics, Inc.
|
60,000 | $852,600 |
All Filings in CELC
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $58,782,100 | 515,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $60,043,480 | 602,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $38,334,400 | 776,000 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||